Gretchen Tamms

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites

Laura L. Hammitt, Ulrike K. Buchwald, Jennifer McCauley, Tulin Shekar et autres

Background/Objectives: American Indian/Alaska Native individuals exhibit a higher prevalence of carriage of Streptococcus pneumoniae and are at increased risk of invasive pneumococcal disease compared with the general US population, driven by persistent inequities in health determinants. Although the use of pneumococcal vaccines …

us, ca (code pays fourni par la source)

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

Tosin Omole, Enrique Pelayo, Aaron S. Weinberg, Spyros Chalkias et autres

The authors would like to make the following corrections to this published paper [...].

us (code pays fourni par la source)

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age

Tosin Omole, Enrique Pelayo, Aaron S. Weinberg, Spyros Chalkias et autres

BACKGROUND/OBJECTIVES: with, or following, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with increased mortality, particularly in older adults. However, vaccination can be an effective preventative measure. This Phase 3 study (NCT05158140) assessed the immunogenicity and safety of co-administering …

us (code pays fourni par la source)

PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children

Timothy J. Chapman, Liset Olarte, Ghassan Dbaibo, Avril Melissa Houston et autres

INTRODUCTION: is a causative agent of pneumonia and acute otitis media (AOM), as well as invasive diseases such as meningitis and bacteremia. PCV15 (V114) is a new 15-valent pneumococcal conjugate vaccine (PCV) approved for use in individuals ≥6 weeks of age for …

us, lb (code pays fourni par la source)

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies

Timothy J. Chapman, Shrita M. Patel, Sheryl Flores, Shengjie Xu et autres

BACKGROUND: Risk of invasive pneumococcal disease is 3-fold higher in preterm versus full-term infants. V114 is a 15-valent pneumococcal conjugate vaccine (PCV) containing the 13 serotypes in PCV13 plus 2 unique serotypes, 22F and 33F. A pooled subgroup analysis was performed in …

us, gb (code pays fourni par la source)

A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)

Marissa B. Wilck, Oliver A. Cornely, Catherine Cordonnier, Juan D. Vélez et autres

BACKGROUND: Individuals who receive allogeneic hematopoietic cell transplant (allo-HCT) are immunocompromised and at high risk of pneumococcal infections, especially in the months following transplant. This study evaluated the safety and immunogenicity of V114 (VAXNEUVANCE; Merck, Sharp & Dohme LLC, a subsidiary of …

us, de, fr, co, se, be, br, il, au (code pays fourni par la source)

Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study

Natalie Banniettis, Michael Horn, Manish Sadarangani, Shrita M. Patel et autres

BACKGROUND AND OBJECTIVES: Disease caused by Streptococcus pneumoniae is associated with considerable morbidity and mortality in children. Pneumococcal conjugate vaccines (PCVs) are well tolerated and effective at reducing pneumococcal disease caused by vaccine serotypes. VAXNEUVANCE (V114) is a 15-valent PCV containing 13 …

us, ca, il, th, au (code pays fourni par la source)

P08 A Phase 1, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (PCV) (V116) in adults

Heather Platt, Doreen Fernsler, Nancy Gallagher, Aditi Sapre et autres

Abstract Background V116, an investigational 21-valent PCV, contains the following pneumococcal polysaccharides (PnPs): 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B, and a de-O-acetylated 15B (deOAc15B). This phase 1 study …

us (code pays fourni par la source)

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel et autres

Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination with 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for at-risk adults. This subgroup analysis from …

us, nz, pl, ca, cl, ru, il (code pays fourni par la source)

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Robert Lupinacci, Richard Rupp, Orasri Wittawatmongkol, Jake D. Jones et autres

BACKGROUND: Pneumococcal disease (PD) remains a major health concern with considerable morbidity and mortality in children. Currently licensed pneumococcal conjugate vaccines (PCVs) confer protection against PD caused by most vaccine serotypes, but non-vaccine serotypes contribute to residual disease. V114 is a 15-valent …

us, th, pr, tr, il, au (code pays fourni par la source)

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION)

Androniki Bili, Scott Dobson, Jeffrey Quinones, Wanatpreeya Phongsamart et autres

us, pr, th, il, au (code pays fourni par la source)

Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study

Charles T. Quinn, Richard T. Wiedmann, Daniel Jarovsky, Eduardo López‐Medina et autres

Sickle cell disease (SCD) is an inherited red blood cell disease that results in a multitude of medical complications, including an increased risk of invasive disease caused by encapsulated bacteria, such as Streptococcus pneumoniae. Pneumococcal vaccines have contributed to a significant reduction …

us, co, pa, il, au (code pays fourni par la source)